MI Visit the ASPET Website
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Summary Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dempsey, P. J.
Right arrow Articles by Raines, E. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dempsey, P. J.
Right arrow Articles by Raines, E. W.
Molecular Interventions 2:136-141 (2002)
© 2002 American Society of Pharmacology and Experimental Therapeutics

Viewpoint

Emerging Roles of TACE as a Key Protease in ErbB Ligand Shedding

Peter J. Dempsey1, Kyle Garton2 and Elaine W. Raines2

1 Pacific Northwest Research Institute, Seattle, WA 98122, USA and
2 Department of Pathology, Harborview Medical Center, University of Washington, Seattle, WA, 98104, USA

SUMMARY

Sunnarborg et al. have published how tumor necrosis factor-{alpha} converting enzyme (TACE) can control the availability of transforming growth factor-{alpha}—a natural ligand for epidermal growth factor receptors (EGFRs)—for EGFRs located at the cell surface. Dempsey, Garton, and Raines examine the ramifications of TACE-dependent proteolytic cleavage of membrane-bound ligands on paracrine, juxtacrine, and autocrine signaling.

The epidermal growth factor (EGF) family and their receptors—the ErbB family of type I receptor tyrosine kinases—participate in development, differentiation, proliferation, and survival (1,2). Hyperactivity of ErbB signaling has also been strongly implicated in human cancer (3), whereas targeted mutation of ErbB1/EGFR in mice results in embryonic and perinatal lethality with epithelial cells being most profoundly affected by receptor loss (4–6). All endogenous ErbB ligands are synthesized as transmembrane precursors that are proteolytically cleaved (see Table 1Go) to release biologically active soluble growth factors, which act in an autocrine or paracrine manner (7) (Figure 1Go). Although in vitro studies have indicated that membrane-anchored ErbB ligand precursors may also be biologically active at the cell surface in a juxtacrine manner (8–11), genetic studies in Drosophila (12–14) and blockade of shedding in mammalian cells (15) highlight a requirement for proteolytic release of ErbB ligands.


View this table:
[in this window]
[in a new window]
  		TABLE 1. MEMBERS OF THE ERBB LIGAND FAMILY SHED BY METALLOPROTEINASES
 


View larger version (48K):
[in this window]
[in a new window]
  		Figure 1. TACE-dependent proteolysis of the proTGF{alpha} extracellular domain as a regulatory event in ErbB1 receptor signaling. Genetic and biochemical data indicate that the release of soluble TGF{alpha} acting either as an autocrine or a paracrine signal is essential to achieve full biological activity in vivo. Data from Sunnarborg et al. suggest that TACE may also be involved in the N-terminal prodomain processing of proTGF{alpha} (16). Many questions still remain about the specificity and regulation of TACE as general ErbB ligand "sheddase." Some of these questions can be divided into three general areas. 1. Secretory Pathway. How is the biosynthesis and activation of TACE regulated and can active TACE cleave substrate during transit through the secretory pathway? 2. Spatial Compartmentalization. What is the trafficking of TACE, what membrane compartments is it localized to and how is access of TACE to substrate regulated? 3. Metalloproteinases. What is the specificity of TACE for other ErbB ligands? Is the catalytic activity of TACE regulated? What is the role of other metalloproteinase(s) in ErbB ligand shedding?

 
The regulation of ErbB ligand presentation and processing has been an area of intense investigation over the last decade and many questions have been raised. Why are ErbB ligands synthesized as transmembrane precursors? Do membrane-anchored ligand precursors and shed soluble ligands have different signaling capacities? How is the proteolytic release of ligands regulated, and what proteases are involved? Progress in regard to better defining the proteases involved in ErbB ligand release, highlighted by the recent publication of Sunnarborg et al., suggests a larger role for the tumor necrosis factor-{alpha} (TNF{alpha}) converting enzyme (TACE/ADAM17) (16).

TACE, a member of a large family of disintegrin-metalloproteinases (ADAMs), is capable of processing diverse substrates including pro-transforming growth factor-{alpha} (proTGF{alpha}), TNF{alpha}, and L-selectin (17). Mice that produce catalytically inactive TACE protein that cannot bind Zn2+ (Tace {Delta}Zn/{Delta}Zn) display a severe phenotype similar to the embryonic and perinatal lethality observed in EGFR-deficient mice (4–6). The eye, hair, and skin phenotypes of newborn Tace {Delta}Zn/{Delta}Zn mice are identical to those previously reported for TGF{alpha}-deficient mice (18,19). Indeed, the involvement of TACE in proTGF{alpha} processing was confirmed by the reduced shedding of endogenous TGF{alpha} from ras- and myc-transformed embryonic fibroblasts derived from Tace {Delta}Zn/{Delta}Zn mice, and by the ability of recombinant TACE to correctly process a proTGF{alpha} juxtamembrane peptide in vitro. Mice lacking functional TACE have additional defects beyond those observed in TGF{alpha}–deficient mice, including defects in: epithelial maturation within multiple organs; formation of the lung vasculature; airway branching; and the spongiotrophoblast layer of the placenta (17,20). Both the decreased size and the delayed cellular differentiation of TACE-deficient lungs are restored by the exogenous addition of soluble EGF in embryonic lung culture (20). Together, these genetic data further support the concept that TACE-dependent cleavage of proTGF{alpha} and other ErbB ligands is essential to development.

The studies by Sunnarborg et al. provide an excellent example of the key criteria needed to unambiguously define a role for TACE in processing of proTGF{alpha}. Previous genetic studies have relied on examining the loss of substrate shedding in ras- and myc-transformed embryonic fibroblasts from Tace {Delta}Zn/{Delta}Zn mice, however it is unclear how transformation and constitutively active Ras signaling may affect proteolytic cleavage. In contrast, Sunnarborg et al. demonstrate defective TGF{alpha} shedding in primary cultures of normal Tace {Delta}Zn/{Delta}Zn keratinocytes, and partially restore shedding by re-expressing TACE in these cells.

Another major limitation in defining the participation of specific ADAMs in ErbB ligand processing has been the difficulty of demonstrating the direct cleavage of ligands, and verifying that the ligands have been processed at the correct sites of proteolysis. In the case of TACE, in vitro assays demonstrated the proteolytic cleavage of TNF{alpha}, L-selectin, and TGF{alpha} juxtamembrane peptides (17,21,22). Sunnarborg et al. have extended this approach to proTGF{alpha} and its N- and C-terminal cleavage site peptides, demonstrating that TACE can correctly cleave both N- and C-terminal cleavage sites. Interestingly, most TACE substrates are cleaved within a short stretch of amino acids located in the juxtamembrane region of the extracellular domain. The possibility that TACE may be involved in both N- and C-terminal proTGF{alpha} cleavage events raises important questions about how TACE, which is an integral transmembrane protein, can recognize and discriminate between cleavage sites that are located within the extracellular domain of the same protein.

The importance of ErbB ligand shedding has also led investigators to examine the regulation and specificity of TACE and other metalloproteinases in the processing of other ErbB ligands. Indeed, the sequential cleavage of the extracellular domain of membrane-anchored EGF-like growth factors is a highly regulated process that can be activated by a wide variety of pharmacological agents as well as physiological stimuli (23–25). Using different experimental approaches, studies have implicated matrix metalloproteinases as well as ADAM proteases in the proteolytic cleavage and shedding of ErbB ligands (Table 1Go). The work by Sunnarborg et al. adds two other ErbB ligands to the list of TACE substrates, with their demonstration that TACE restores cleavage of transfected amphiregulin and HB-EGF in ras- and myc-transformed embryonic fibroblasts from Tace {Delta}Zn/{Delta}Zn mice. However, as detailed in Table 1Go, data for none of the other ligands or proteases provide the ideal composite of data to demonstrate loss of function in null cells, restoration by the candidate protease, and evidence of direct cleavage. In fact, in the case of ADAM9 as a candidate protease for the cleavage of HB-EGF, constitutive and stimulated ectodomain shedding of HB-EGF is comparable in embryonic fibroblasts isolated from ADAM9–/– and from wild-type mice, arguing against an essential role of ADAM9 in HB-EGF shedding in these cells (26).

The complexities associated with both ligand and protease processing also contribute to the difficulties in unambiguously assigning a role for a particular protease to processing of an identified ligand. As depicted in Figure 1Go, ErbB ligands move through the secretory pathway where different modifications and cleavage events can take place. In Drosophila, the activity and release of the soluble ErbB-like ligand, Spitz, is regulated by two other proteins, Star and Rhomboid (13,27,28). Star chaperones the Spitz precursor in the endoplasmic reticulum and directs its transport to the Golgi complex (29). Once in the Golgi apparatus, Rhomboid, a novel intramembrane serine protease, cleaves the Spitz pro-protein to initiate secretion (30). By analogy to the regulation of Spitz processing and release, any perturbation that interferes with processing and trafficking of ErbB ligands could appear to inhibit ligand cleavage and release. The overexpression of protease-inactive ADAM mutants may induce such perturbation. As pointed out by Sunnarborg et al., heterozygous Tace +/{Delta}Zn mice display a wild type phenotype indicating that protease-inactive mutants do not function as dominant-negative proteins. In light of the complex and poorly understood biosynthesis and trafficking of ADAMs in the secretory pathway, the studies using overexpression of ADAM mutants should be viewed with caution, and other substrates and ADAM mutants should be used as controls. Thus, understanding the regulation of biosynthesis and trafficking of both ErbB ligands and their candidate proteases will be critical to defining the rate-limiting steps in proteolytic release of ErbB ligands.

Most ADAMs implicated in ErbB ligand processing are ubiquitously expressed, raising the possibility that distinct ADAM specificity for ligand processing may reflect variations in signaling and regulation of ADAM proteolytic activity in different cell types. Although multiple activators of ErbB ligand shedding have been identified (23–25), the proteases responsible for the shedding per se have not been completely characterized. For further progress to be made in understanding the mechanisms regulating these "sheddases," the experimental criteria required to identify candidate metalloproteinase(s) must be clearly defined. Sunnarborg et al. have begun to address the role and specificity of TACE in ErbB ligand processing, although many questions remain.

Data demonstrating a critical role for the proteolytic cleavage of ErbB ligands in ErbB signaling have created a fundamental paradigm shift in our understanding of the biology of ErbB ligand precursors. Numerous in vitro and in vivo studies support the concept that sequential processing of membrane-anchored ErbB ligands provides a mechanism for exquisite control over the temporal and spatial presentation of ligands to receptors (31–39). Thus, sequential processing can directly regulate the ability of a particular ligand to switch function from a potential juxtacrine mode to an autocrine or paracrine mode (8–11) (Figure 1Go). The studies by Sunnarborg et al. and others have established that the release of soluble ErbB ligands is a key upstream regulatory event in ErbB receptor signaling, and have thus identified protein processing as a target for therapeutic intervention (15–17,40–43). For example, the use of either neutralizing antibodies to the ErbB1 receptor, or metalloproteinase inhibitors to effectively inhibit ErbB signaling, can inhibit the in vitro autocrine-dependent proliferation and migration of mammary epithelial cells (15). Additionally, in these mammary epithelial cells, autocrine presentation of a protease-cleavable ligand results in enhanced, persistent cell migration in a particular direction, whereas stimulation by constitutively secreted ligand results in a scattering response in these cells (41). Is there any physiological role for juxtacrine signaling by ErbB ligand precursors in vivo? Or is the primary role of the membrane-anchoring domains of these ligands the spatial regulation of release to appropriate cellular compartments? Answers to these questions will shape our paradigms of ErbB ligand signaling in the future.


Peter J. Dempsey, PhD, is a Principal Scientist at Pacific Northwest Research Institute. Address comments to PJD. E-mail: PDempsey{at}pnri.org


Kyle Garton, PhD, is currently finishing his MD training in the MSTP program at the University of Washington Medical School. The picture above was taken April 17, 2002, the day he completed his final examination for his Doctoral Degree.Elaine W. Raines, MS, is a Research Professor in the Department of Pathology at the University of Washington Medical School.

References

  1. Schweitzer, R. and Shilo, B.Z. A thousand and one roles for the Drosophila EGF receptor. Trends Genet. 13, 191–196 (1997).[CrossRef][Medline]
  2. Bogdan, S. and Klambt, C. Epidermal growth factor receptor signaling. Curr. Biol. 11, R292–R295 (2001).[CrossRef][Medline]
  3. Yarden, Y. and Sliwkowski, M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2, 127–137 (2001).[CrossRef][Medline]
  4. Miettinen, P.J., Berger, J.E., Meneses, J., Phung, Y., Pedersen, R.A., Werb, Z., and Derynck, R. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 376, 337–341 (1995).[CrossRef][Medline]
  5. Threadgill, D.W., Dlugosz, A.A., Hansen, L.A. et al. Targeted disruption of mouse EGF receptor: Effect of genetic background on mutant phenotype. Science 269, 230–234 (1995).[Abstract/Free Full Text]
  6. Sibilia, M. and Wagner, E.F. Strain-dependent epithelial defects in mice lacking the EGF receptor Science 269, 234–238 (1995). [published erratum appears in Science 269, 909 (1995)][Abstract/Free Full Text]
  7. Massagué, J. and Pandiella, A. Membrane-anchored growth factors. Annu. Rev. Biochem. 62, 515–541 (1993).[CrossRef][Medline]
  8. Wong, S.T., Winchell, L.F., McCune, B.K., Earp, H.S., Teixidó, J., Massagué, J., Herman, B., and Lee, D.C. The TGF-{alpha} precursor expressed on the cell surface binds to the EGF receptor on adjacent cells, leading to signal transduction. Cell 56, 495–506 (1989).[CrossRef][Medline]
  9. Brachmann, R., Lindquist, P.B., Nagashima, M., Kohr, W., Lipari, T., Napier, M., and Derynck, R. Transmembrane TGF-{alpha} precursors activate EGF/TGF-{alpha} receptors. Cell 56, 691–700 (1989).[CrossRef][Medline]
  10. Blasband, A.J., Gilligan, D.M., Winchell, L.F., Wong, S.T., Luetteke, N.C., Rogers, K.T., and Lee, D.C. Expression of the TGF-{alpha} integral membrane precursor induces transformation of NRK cells. Oncogene 5, 1213–1221 (1990).[Medline]
  11. Higashiyama, S., Iwamoto, R., Goishi, K., Raab, G., Taniguchi, N., Klagsbrun, M., and Mekada, E. The membrane protein CD9/DRAP 27 potentiates the juxtacrine growth factor activity of the membrane-anchored heparin-binding EGF-like growth factor. J. Cell Biol. 128, 929–938 (1995).[Abstract/Free Full Text]
  12. Freeman, M. The spitz gene is required for photoreceptor determination in the Drosophila eye where it interacts with the EGF receptor. Mech. Dev. 48, 25–33 (1994).[CrossRef][Medline]
  13. Golembo, M. Raz, E., and Shilo, B.Z. The Drosophila embryonic midline is the site of Spitz processing, and induces activation of the EGF receptor in the ventral ectoderm. Development 122, 3363–3370 (1996).[Abstract]
  14. Schweitzer, R., Shaharabany, M., Seger, R., and Shilo, B.Z. Secreted Spitz triggers the DER signaling pathway and is a limiting component in embryonic ventral ectoderm determination. Genes Dev. 9, 1518–1529 (1995).[Abstract/Free Full Text]
  15. Dong, J., Opresko, L.K., Dempsey, P.J., Lauffenburger, D.A., Coffey, R.J., and Wiley, H.S. Metalloprotease-mediated ligand release regulates autocrine signaling through the epidermal growth factor receptor. Proc. Natl. Acad. Sci. U.S.A. 96, 6235–6240 (1999).[Abstract/Free Full Text]
  16. Sunnarborg, S.W., Hinkle, C.L., Stevenson, M. et al. Tumor necrosis factor-{alpha} converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability. J. Biol. Chem. 271, 12838–12845 (2002).
  17. Peschon, J.J., Slack, J.L., Reddy, P. et al. An essential role for ectodomain shedding in mammalian development. Science 282, 1281–1284 (1998).[Abstract/Free Full Text]
  18. Luetteke, N.C., Qiu, T.H., Peiffer, R.L., Oliver, P., Smithies, O., and Lee, D.C. TGF-{alpha} deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice. Cell 73, 263–278 (1993).[CrossRef][Medline]
  19. Mann, G.B., Fowler K.J., Gabriel, A., Nice, E.C., Williams, R.L., and Dunn, A.R. Mice with a null mutation of the TGF-{alpha} gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation. Cell 73, 249–261 (1993).[CrossRef][Medline]
  20. Zhao, J. Liang, S.X., Savas, L., and Banner, B.F. An immunostaining panel for diagnosis of malignancy in mucinous tumors of the pancreas. Arch. Pathol. Lab. Med. 125, 765–769 (2001).[Medline]
  21. Black, R.A., Rauch, C.T., Kozlosky, C.J. et al. A metalloproteinase disintegrin that releases tumour necrosis factor-{alpha} from cells. Nature 385, 729–733 (1997).[CrossRef][Medline]
  22. Moss, M.L., Jin, S.L., Milla, M.E. et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour necrosis factor-{alpha}. Nature 385, 733–736 (1997). [published erratum appears in Nature 386, 738 (1997)][CrossRef][Medline]
  23. Pandiella, A. and Massagué, J. Cleavage of the membrane precursor for transforming growth factor-{alpha} is a regulated process. Proc. Natl. Acad. Sci. U.S.A. 88, 1726–1730 (1991).[Abstract/Free Full Text]
  24. Merlos-Suárez, A., Ruiz-Paz, S., Baselga, J., Arribas, J. Metalloprotease-dependent protransforming growth factor-{alpha} ectodomain shedding in the absence of tumor necrosis factor-{alpha}–converting enzyme. J. Biol. Chem. 276, 48510–48517 (2001).[Abstract/Free Full Text]
  25. Montero, J.C., Yuste, L., Díaz-Rodríguez, E., Esparís-Ogando, A., Pandiella, Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases. Biochem. J. 363, 211–221 (2002).[CrossRef][Medline]
  26. Weskamp, G., Cai, H., Brodie, T.A., Higashyama, S., Manova, K., Ludwig, T., and Blobel, C.P. Mice lacking the metalloprotease-disintegrin MDC9 (ADAM9) have no evident major abnormalities during development or adult life. Mol. Cell. Biol. 22, 1537–1544 (2002).[Abstract/Free Full Text]
  27. Guichard, A., Biehs, B., Sturtevant, M.A., Wickline, L., Chacko, J., Howard, K., and Bier, E. rhomboid and Star interact synergistically to promote EGFR/MAPK signaling during Drosophila wing vein development. Development 126, 2663–2676 (1999).[Abstract]
  28. Bang, A.G. and Kintner, C. Rhomboid and Star facilitate presentation and processing of the Drosophila TGF-{alpha} homolog Spitz. Genes Dev. 14, 177–186 (2000).[Abstract/Free Full Text]
  29. Lee, J.R., Urban, S., Garvey, C.F., and Freeman, M. Regulated intracellular ligand transport and proteolysis control EGF signal activation in Drosophila. Cell 107, 161–171 (2001).[CrossRef][Medline]
  30. Urban, S., Lee, J.R., and Freeman, M. Drosophila rhomboid-1 defines a family of putative intramembrane serine proteases. Cell 107, 173–182 (2001).[CrossRef][Medline]
  31. Lanzrein, M., Garred, O., Olsnes, S., and Sandvig, K. Diphtheria toxin endocytosis and membrane translocation are dependent on the intact membrane-anchored receptor (HB-EGF precursor): Studies on the cell-associated receptor cleaved by a metalloprotease in phorbol-ester-treated cells. Biochem. J. 310, 285–289 (1995).
  32. Baselga, J., Mendelsohn, J., Kim, Y.M., and Pandiella, A. Autocrine regulation of membrane transforming growth factor-{alpha} cleavage. J. Biol. Chem. 271, 3279–3284 (1996).[Abstract/Free Full Text]
  33. Arribas, J., Coodly, L., Vollmer, P., Kishimoto, T.K., Rose-John, S., and Massagué, J. Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. J. Biol. Chem. 271, 11376–11382 (1996).[Abstract/Free Full Text]
  34. Dempsey, P.J., Meise, K.S., Yoshitake, Y., Nishikawa, K., and Coffey, R.J. Apical enrichment of human EGF precursor in Madin-Darby canine kidney cells involves preferential basolateral ectodomain cleavage sensitive to a metalloprotease inhibitor. J. Cell Biol. 138, 747–758 (1997).[Abstract/Free Full Text]
  35. Brown, C.L., Meise, K.S., Plowman, G.D., Coffey, R.J., and Dempsey, P.J. Cell surface ectodomain cleavage of human amphiregulin precursor is sensitive to a metalloprotease inhibitor: Release of a predominant N-glycosylated 43-kDa soluble form. J. Biol. Chem. 273, 17258–17268 (1998).[Abstract/Free Full Text]
  36. Dethlefsen, S.M., Raab, G., Moses, M.A., Adam, R.M., Klagsbrun, M., and Freeman, M.R. Extracellular calcium influx stimulates metalloproteinase cleavage and secretion of heparin-binding EGF-like growth factor independently of protein kinase C. J. Cell. Biochem. 69, 143–153 (1998).[CrossRef][Medline]
  37. Merlos-Suárez, A. and Arribas, J. Mechanisms controlling the shedding of transmembrane molecules. Biochem. Soc. Trans. 27, 243–246 (1999).[Medline]
  38. Gechtman, Z., Alonso, J. L., Raab, G., Ingber, D.E., and Klagsbrun, M. The shedding of membrane-anchored heparin-binding epidermal-like growth factor is regulated by the Raf/mitogen-activated protein kinase cascade and by cell adhesion and spreading. J. Biol. Chem. 274, 28828–28835 (1999).[Abstract/Free Full Text]
  39. Vecchi, M., Rudolph-Owen, L.A., Brown, C.L., Dempsey, P.J., and Carpenter, G. Tyrosine phosphorylation and proteolysis. Pervanadate-induced, metalloprotease-dependent cleavage of the ErbB-4 receptor and amphiregulin. J. Biol. Chem. 273, 20589–20595 (1998).[Abstract/Free Full Text]
  40. Dell, K.M., Nemo, R., Sweeney Jr., W.E., Levin, J.I., Frost, P., and Avner, E.D. A novel inhibitor of tumor necrosis factor-alpha converting enzyme ameliorates polycystic kidney disease. Kidney Int. 60, 1240–1248 (2001).[CrossRef][Medline]
  41. Maheshwari, G., Wiley, H.S., and Lauffenburger, D.A. Autocrine epidermal growth factor signaling stimulates directionally persistent mammary epithelial cell migration. J. Cell Biol. 155, 1123–1128 (2001).[Abstract/Free Full Text]
  42. Asakura, M., Kitakaze, M., Takashima, S. et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy. Nat. Med. 8, 35–40 (2002).[CrossRef][Medline]
  43. Lemjabbar, H. and Basbaum, C. Platelet-activating factor receptor and ADAM10 mediate responses to Staphylococcus aureus in epithelial cells. Nat. Med. 8, 41–46 (2002).[CrossRef][Medline]
  44. Izumi, Y., Hirata, M., Hasuwa, H. et al. A metalloprotease-disintegrin, MDC9/meltrin-{gamma}/ADAM9 and PKC{delta} are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. EMBO J. 17, 7260–7272 (1998).[CrossRef][Medline]
  45. Suzuki, M., Raab, G., Moses, M.A., Fernandez, C.A., and Klagsbrun, M. Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J. Biol. Chem. 272, 31730–31737 (1997).[Abstract/Free Full Text]
  46. Yu, W.H., Woessner Jr., J.F., McNeish, J.D., and Stamenkovic, I. CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev. 16, 307–323 (2002).[Abstract/Free Full Text]
  47. Shirakabe, K., Wakatsuki, S., Kurisaki, T., Fujisawa-Sehara, A. Roles of meltrin-ß /ADAM19 in the processing of neuregulin. J. Biol. Chem. 276, 9352–9358 (2001).[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
N. Ali and V. Knauper
Phorbol Ester-induced Shedding of the Prostate Cancer Marker Transmembrane Protein with Epidermal Growth Factor and Two Follistatin Motifs 2 Is Mediated by the Disintegrin and Metalloproteinase-17
J. Biol. Chem., December 28, 2007; 282(52): 37378 - 37388.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Interv.Home page
L. M. Graves, J. Han, and H. S. Earp III
Transactivation of the EGF Receptor: Is the PDGF Receptor an Unexpected Accomplice?
Mol. Interv., July 1, 2002; 2(4): 208 - 212.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Summary Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dempsey, P. J.
Right arrow Articles by Raines, E. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dempsey, P. J.
Right arrow Articles by Raines, E. W.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ASPET Journals Pharmacological Reviews Drug Metabolism and Disposition
Molecular Interventions Molecular Pharmacology J Pharmacology and Exp Therapeutics
Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.